Literature DB >> 30616438

Prolonged survival with increasing duration of lenalidomide maintenance after autologous transplant for multiple myeloma.

Isabel G Amsler1, Barbara Jeker1, Behrouz Mansouri Taleghani2, Ulrike Bacher2, Daniel Betticher3, Thomas Egger4, Thilo Zander5, Jean-Marc Luethi6, Urban Novak1, Thomas Pabst1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30616438     DOI: 10.1080/10428194.2018.1473577

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


× No keyword cloud information.
  4 in total

1.  Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma.

Authors:  Rafael Alonso; María-Teresa Cedena; Sandy Wong; Nina Shah; Rafael Ríos-Tamayo; José M Moraleda; Javier López-Jiménez; Cristina García; Natasha Bahri; Antonio Valeri; Ricardo Sánchez; Luis Collado-Yurrita; Thomas Martin; Jeffrey Wolf; Juan-José Lahuerta; Joaquín Martínez-López
Journal:  Blood Adv       Date:  2020-05-26

2.  The Effect of Duration of Lenalidomide Maintenance and Outcomes of Different Salvage Regimens in Patients with Multiple Myeloma (MM).

Authors:  Matthew Ho; Saurabh Zanwar; Prashant Kapoor; Morie Gertz; Martha Lacy; Angela Dispenzieri; Suzanne Hayman; David Dingli; Francis Baudi; Eli Muchtar; Nelson Leung; Taxiarchis Kourelis; Rahma Warsame; Amie Fonder; Lisa Hwa; Miriam Hobbs; Robert Kyle; S Vincent Rajkumar; Shaji Kumar
Journal:  Blood Cancer J       Date:  2021-09-22       Impact factor: 9.812

3.  Cost-Effectiveness of Post-Autotransplant Lenalidomide in Persons with Multiple Myeloma.

Authors:  Monia Marchetti; Robert Peter Gale; Giovanni Barosi
Journal:  Mediterr J Hematol Infect Dis       Date:  2021-05-01       Impact factor: 2.576

4.  Adding bendamustine to melphalan before ASCT improves CR rate in myeloma vs. melphalan alone: A randomized phase-2 trial.

Authors:  Sarah Farag; Ulrike Bacher; Barbara Jeker; Myriam Legros; Gaelle Rhyner; Jean-Marc Lüthi; Julian Schardt; Thilo Zander; Michael Daskalakis; Behrouz Mansouri; Chantal Manz; Thomas Pabst
Journal:  Bone Marrow Transplant       Date:  2022-04-20       Impact factor: 5.174

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.